Preventing SARS-CoV-2 entry into lung cells by inhibiting TMPRSS2, the host cell activator, and the observed therapeutic effects of camostat mesylate in critically ill COVID-19 patients indicate promising treatment directions [32]. This evidence concerns the gene TMPRSS2 and COVID-19.